Trials / Completed
CompletedNCT04553939
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
Phase II Study of Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Stage II-IIIB Bladder Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a pre-surgical study involving subjects with muscle invasive bladder urothelial cancer, who are candidates for cisplatin ineligible neoadjuvant therapy. It is a one-arm phase II study in single center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles. |
| DRUG | Gemcitabine | Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles. |
Timeline
- Start date
- 2021-01-04
- Primary completion
- 2023-04-12
- Completion
- 2025-04-12
- First posted
- 2020-09-18
- Last updated
- 2026-01-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04553939. Inclusion in this directory is not an endorsement.